AMRX Earnings Date 2026
Amneal Pharmaceuticals, Inc. Class A Common Stock earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$17.68
+1.20% today
Earnings Metrics
EPS (TTM)
$0.01
P/E Ratio
1298.0
Revenue Growth
11.7%
Market Cap
$5.2B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $-0.38 | $2.79B | $-0.07B |
| Q4 2023 | $-0.48 | $2.39B | $-0.05B |
Trading Around AMRX Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full AMRX Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is AMRX next earnings date?
AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is AMRX earnings per share (EPS)?
AMRX's current earnings per share (EPS) is $0.01. With a P/E ratio of 1298.0, the market values each dollar of earnings at $1298.0.
How often does AMRX report earnings?
Like most publicly traded US companies, AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does AMRX report earnings?
AMRX typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has AMRX performed in recent earnings?
In the most recent quarter (Q4 2024), AMRX reported EPS of $-0.38 on revenue of $2.79B.
What do analysts expect for AMRX earnings?
Analyst expectations for AMRX earnings can vary. The company has shown positive revenue growth of 11.7%. View the full analyst ratings page for detailed expectations.